Anlotinib plus camrelizumab achieved long‐term survival in a patient with metastatic esophageal neuroendocrine carcinoma
Abstract Background Esophageal neuroendocrine carcinoma (NEC) is a rare cancer with an extremely poor prognosis. The average overall survival of patients with metastatic disease is only 1 year. The efficacy of anti‐angiogenic agents combined with immune checkpoint inhibitors remains unknown. Case Pr...
| Egile Nagusiak: | , , , , , , , |
|---|---|
| Formatua: | Artikulua |
| Hizkuntza: | English |
| Argitaratua: |
Wiley
2023-09-01
|
| Saila: | Cancer Reports |
| Gaiak: | |
| Sarrera elektronikoa: | https://doi.org/10.1002/cnr2.1855 |